Clinical Trials Logo

Clinical Trial Summary

This is a phase I, single-blind, randomized, placebo-controlled, single-center study in healthy subjects using a staggered approach to dosing.

30 subjects will be randomized to receive 10 μg Flexyn2a candidate vaccine with or without adjuvant or placebo.


Clinical Trial Description

A total of 30 subjects will be randomly assigned to one of 3 different arms in order to evaluate the safety, tolerability and immunogenicity of a candidate vaccine, formulated with or without adjuvant, and the outcome compared to a placebo control group.

For each active treatment group, 12 subjects will be injected twice with 10 μg Flexyn2a candidate vaccine 4 weeks apart. A control group with 6 subjects will be injected following the same schedule with a placebo solution. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT02388009
Study type Interventional
Source LimmaTech Biologics AG
Contact
Status Completed
Phase Phase 1
Start date February 2015
Completion date September 2015

See also
  Status Clinical Trial Phase
Completed NCT02797236 - SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers Phase 1
Completed NCT04056117 - A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Phase 1/Phase 2
Not yet recruiting NCT05959616 - Shigella Sonnei 53G Human Infection Study in Kenyan Adults Phase 1
Completed NCT02445963 - Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Phase 1
Not yet recruiting NCT05961059 - InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia Phase 1
Completed NCT00485134 - Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Phase 1/Phase 2
Completed NCT01369927 - Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Phase 1
Completed NCT02034500 - Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults Phase 1
Completed NCT01509846 - Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults Phase 1
Completed NCT02105714 - Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders N/A
Withdrawn NCT01399424 - Shigella Sonnei OSPC-rDT Conjugate Vaccine Phase 1
Completed NCT00800930 - Therapeutic Induction of Endogenous Antibiotics Phase 2
Completed NCT00368316 - Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Phase 3
Recruiting NCT05182749 - Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis Phase 1/Phase 2
Completed NCT02017899 - A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. Phase 1
Completed NCT01069471 - Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella Phase 1
Completed NCT02646371 - Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a Phase 2
Recruiting NCT05156528 - Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years Phase 3
Completed NCT03854929 - Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery Phase 4
Recruiting NCT05121974 - Tebipenem Trial in Children With Shigellosis Phase 2